News of Note—Meissa’s chairman from J&J, Takeda and more

non
In this week's news of note, Meissa named a former Johnson & Johnson executive as chairman. (Pixabay)

Here's some other vaccine news of note for the week.

> Meissa Vaccines named Lawrence Blatt, Ph.D., Johnson & Johnson’s recent global head of infectious diseases and vaccines, as its chairman. Release

Takeda established a Center of Excellence in Singapore for vaccine development. It will hire and train local talent to work on the company's current and future vaccine candidates. Asian Scientist article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

> An American expert told the Philippine Senate that he warned Sanofi on the health risks of Dengvaxia in 2016. The Manila Times article

PharmaJet is close to completing a $5 million financing round to fund the production of 5 million syringes to deliver the polio vaccine. MedCity News article

Valneva started a phase 1 study on its live-attenuated, single-dose vaccine candidate against Chikungunya. Release

> Researchers from Cardiff University have created the world’s first synthetic flu vaccine, which is given orally and is stable at room temperature. Cardiff University article

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

With COVID vaccinations expected to start in the coming weeks, 2021 is shaping up to be quite a year for the companies with leading vaccines.

The U.K. became the first Western country to authorize a COVID-19 vaccine, making the Pfizer/BioNTech shot the first mRNA vaccine for widespread use.